Skip to main content
Clinical Trials/NCT02145663
NCT02145663
Completed
Not Applicable

Helsinki Ultra-acute Stroke Biomarker Study

Helsinki University Central Hospital1 site in 1 country1,046 target enrollmentMay 2013
ConditionsAcute Stroke

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Acute Stroke
Sponsor
Helsinki University Central Hospital
Enrollment
1046
Locations
1
Primary Endpoint
Diagnostic accuracy of biomarkers for identifying ischemic stroke, transient ischemic attack, intracerebral hemorrhage and stroke mimics.
Status
Completed
Last Updated
10 years ago

Overview

Brief Summary

The aim of this study is to establish diagnostic and predictive biomarkers for patients with suspected acute stroke, that are transported by EMS as candidates for thrombolytic treatment. The study focuses on the ultra acute phase, <4.5 hours from symptom onset, including the prehospital setting. Analyses will include known biomarkers (e.g. GFAP, NR2 peptide) and a discovery phase for novel markers. Patient outcome will be evaluated at 3 month using the modified Rankin Scale (mRS).

Registry
clinicaltrials.gov
Start Date
May 2013
End Date
February 2016
Last Updated
10 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Perttu Lindsberg

Professor

Helsinki University Central Hospital

Eligibility Criteria

Inclusion Criteria

  • Acute stroke suspected by EMS personnel
  • Transport to tertiary hospital as possible candidate for thrombolytic treatment of ischemic stroke
  • Successful prehospital blood sampling by EMS personnel

Exclusion Criteria

  • Unsuccessful prehospital blood sampling by EMS personnel

Outcomes

Primary Outcomes

Diagnostic accuracy of biomarkers for identifying ischemic stroke, transient ischemic attack, intracerebral hemorrhage and stroke mimics.

Time Frame: 90 days +/- 5 days

Metrics: Receiver operating characteristic curve analysis, sensitivity, specificity, positive predictive value, negative predictive value

Predictive accuracy of biomarkers for identifying patients not responding to thrombolytic treatment.

Time Frame: 90 days +/- 5 days

Metrics: Receiver operating characteristic curve analysis, sensitivity, specificity, positive predictive value, negative predictive value

Predictive accuracy of biomarkers for identifying patients facing hemorrhagic complications of thrombolytic treatment

Time Frame: 90 days +/- 5 days

Metrics: Receiver operating characteristic curve analysis, sensitivity, specificity, positive predictive value, negative predictive value

Predictive accuracy of biomarkers for predicting outcome

Time Frame: 90 days +/- 5 days

Metrics: Receiver operating characteristic curve analysis, sensitivity, specificity, positive predictive value, negative predictive value

Study Sites (1)

Loading locations...

Similar Trials